Performance

GHRP-2

Also known as: Growth Hormone Releasing Peptide-2, Pralmorelin

RouteSubcutaneous

UK StatusGHRP-2 occupies a complex regulatory position in the UK. The MHRA (Medicines and Healthcare products Regulatory Agency) has not licensed Pralmorelin (GHRP-2's International Nonproprietary Name) as a prescription medicine for human therapeutic use. This regulatory status means GHRP-2 is classified as an unlicensed medicinal product. It is not controlled under the Misuse of Drugs Act, so possession for personal use is not illegal. However, it cannot be legally marketed or sold for human consumption without appropriate medical licensing and regulatory approval. Most UK suppliers market GHRP-2 as a "research chemical" with clear disclaimers stating "not for human consumption" to comply with current regulations. Some private medical clinics may prescribe it under special licensing arrangements for specific medical conditions, though this practice operates within complex regulatory frameworks. Healthcare providers can legally prescribe unlicensed medicines under certain circumstances outlined in MHRA guidance, but most NHS practitioners will not prescribe research peptides due to liability and evidence limitations. The MHRA continues to monitor the peptide market and has increased scrutiny of various compounds since 2020. While no specific enforcement actions have targeted GHRP-2 users, the regulatory environment remains subject to change. For comprehensive information about current peptide regulations and how they affect different substances, consult our detailed [UK peptide legality guide](/learn/uk-peptide-legality). Given the evolving regulatory landscape, staying informed about current legal status is essential before considering any use. **Important Disclaimer:** This information is provided for educational purposes only and should not be considered legal advice. Always consult current MHRA guidance and qualified legal professionals for specific legal questions.

Overview

GHRP-2 (Growth Hormone Releasing Peptide-2), also known as Pralmorelin, is a synthetic peptide designed to stimulate growth hormone release with reduced appetite effects compared to its predecessor [GHRP-6](/peptides/ghrp-6). Developed in the 1990s as a synthetic analogue of ghrelin, this hexapeptide has been studied for its selective GH receptor targeting.

Unlike natural ghrelin, GHRP-2 was engineered for greater selectivity. It primarily targets growth hormone secretagogue receptors in the pituitary whilst producing less pronounced appetite stimulation compared to GHRP-6. This selectivity profile has made it a subject of interest for researchers studying body composition and growth hormone deficiency.

Research suggests potential applications for growth hormone deficiency in both paediatric and adult populations, though clinical studies show varying degrees of efficacy. Some research indicates dose-dependent GH increases, though responses vary significantly between individuals and age groups (Arvat et al., 1997). These effects require careful medical evaluation and supervision.

Beyond medical research applications, GHRP-2 has gained attention in anti-ageing and performance research circles. Some studies suggest potential improvements in [sleep quality](/learn/peptides-sleep), recovery markers, and gradual body composition changes, though long-term data remains limited. Effects typically develop gradually over extended periods rather than producing immediate transformations.

Within the [growth hormone secretagogue](/learn/growth-hormone-secretagogues) family, GHRP-2 offers a balance between potency and tolerability. While [Ipamorelin](/peptides/ipamorelin) demonstrates a milder side effect profile and [CJC-1295](/peptides/cjc-1295) provides extended duration of action, GHRP-2 occupies a middle position in terms of both effectiveness and tolerability. Research has explored combining it with [CJC-1295](/peptides/cjc-1295) for potentially synergistic effects, as both compounds work through complementary pathways.

The compound requires careful timing and cycling protocols to maintain effectiveness. Its 2-3 hour duration of action makes it suitable for multiple daily dosing regimens, typically administered on an empty stomach for optimal absorption. Our [reconstitution calculator](/tools/reconstitution) can help determine precise dosing from research-grade preparations.

**Important Medical Disclaimer:** GHRP-2 is not approved for human therapeutic use in the UK. Any medical use should only occur under qualified medical supervision with proper monitoring and evaluation. This information is provided for educational purposes only.

Mechanism of Action

GHRP-2 operates through the growth hormone secretagogue receptor type 1a (GHSR-1a)—the same receptor system that responds to the body's natural ghrelin, but with enhanced selectivity compared to ghrelin's broader metabolic effects.

The GHSR-1a receptor functions as a key regulatory mechanism located in the hypothalamus and pituitary gland. When GHRP-2 binds to this receptor, it initiates a cellular cascade that ultimately signals the pituitary to release stored growth hormone. Unlike direct growth hormone administration, this process works through the body's existing regulatory machinery.

The molecular pathway involves phospholipase C activation, which increases intracellular calcium levels and activates protein kinase C. This biochemical cascade stimulates somatotroph cells in the anterior pituitary to release growth hormone in pulsatile patterns that more closely resemble natural physiological rhythms.

GHRP-2 also influences hypothalamic control centres that regulate GH release. Research indicates it may reduce somatostatin secretion—the hormone that normally inhibits growth hormone production—whilst potentially encouraging growth hormone-releasing hormone (GHRH) release (Kojima et al., 1999). This dual mechanism creates conditions that may support sustained GH elevation.

The peptide's selectivity profile distinguishes it from [GHRP-6](/peptides/ghrp-6), which activates multiple receptor pathways and produces more pronounced appetite effects. GHRP-2 was designed to minimise certain off-target effects, particularly hunger stimulation, whilst maintaining potent growth hormone releasing capabilities. This selectivity makes it particularly suitable for applications where appetite stimulation is undesirable.

The compound's effects extend beyond immediate GH release. Elevated growth hormone typically stimulates IGF-1 production in the liver, creating secondary effects that may influence various physiological processes including protein synthesis, fat metabolism, and tissue repair. This IGF-1 response contributes to many of the longer-term effects observed in research studies.

Unlike synthetic growth hormone replacement, GHRP-2 works through existing physiological pathways, potentially allowing the body to maintain some natural regulatory mechanisms. When combined with [CJC-1295](/peptides/cjc-1295), which may extend the duration of natural GHRH activity, research suggests potentially enhanced and more sustained responses, though individual outcomes vary considerably.

For more detailed information about growth hormone pathways, see our [HGH therapy guide](/treatments/hgh-therapy).